GlassScriptPhysician profile
James Luke Ellenburg
NPI 1205290087
$3,109.85
in general payments reported to CMS, 2019-2025
28 companies · $737 in 2025
The $737 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2021: $352 · 2022: $553 · 2023: $822 · 2024: $533 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,092.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $466.85 | 2022-2024 | Axonics |
| Sumitomo Pharma America, INC. | $360.50 | 2023-2025 | Gemtesa, Orgovyx |
| Procept Biorobotics Corporation | $283.94 | 2023-2025 | Aquabeam System, Aquabeam Robotic System |
| Astellas Pharma US INC | $225.67 | 2023-2025 | Xtandi |
| Endo Pharmaceuticals INC. | $200.88 | 2021-2022 | |
| Abbvie INC. | $187.32 | 2021-2025 | |
| Pfizer INC. | $164.48 | 2022-2025 | |
| Boston Scientific Corporation | $145.33 | 2019-2022 | |
| Medtronic, INC. | $138.00 | 2021-2023 | Interstim |
| Olympus America INC. | $97.67 | 2023-2025 | Itind System |
| Laborie Medical Technologies Corp. | $97.26 | 2024-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Myovant Sciences INC. | $95.15 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $81.25 | 2021-2023 | Provenge |
| Progenics Pharmaceuticals, INC. | $64.18 | 2022-2025 | |
| Coloplast Corp | $62.08 | 2022-2025 | Titan |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $58.48 | 2022-2024 | Jelmyto |
| Janssen Biotech, INC. | $56.40 | 2023-2025 | Erleada |
| Ferring Pharmaceuticals INC. | $50.47 | 2024-2025 | Adstiladrin |
| Urovant Sciences INC | $49.36 | 2022 | |
| Myriad Genetic Laboratories, INC. | $38.92 | 2025 | Prolaris |
| Intuitive Surgical, INC. | $34.17 | 2022 | |
| Baxter Healthcare | $24.43 | 2025 | Floseal |
| Calyxo, INC. | $23.71 | 2025 | Cvac Aspiration System |
| Bayer Healthcare Pharmaceuticals INC. | $23.16 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $22.13 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.24 | 2025 | |
| Immunitybio, INC. | $21.19 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $15.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ellenburg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.